National Resilience, Inc.

The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit

PureTech Health plc, after the multibillion-dollar success of its last neuropsychiatry venture Karuna Therapeutics Inc., launched Seaport Therapeutics in April with $100m in series A funding and on 21

In the more than six years since the US Food and Drug Administration approved Novartis AG ’s Kymriah (tisagenlecleucel) and Kite Pharma’s – now part of Gilead Sciences, Inc. – Yescarta (axicabtagen

Alzheimer’s disease is top of mind due to the millions of people in need of effective treatments and the rapid rise in the AD population globally – and because the first disease-modifying therapy has